CalciMedica Inc. (NASDAQ:CALC) Stock Short Interest Jumps 178.0%

CalciMedica Inc. (NASDAQ:CALC) was the target of a significant increase in short interest in the month of October. As of October 30th, there was short interest totaling 171,388 shares, an increase of 178.0% from the October 15th total of 61,641 shares. Based on an average trading volume of 96,501 shares, the days-to-cover ratio is currently 1.8 days. Approximately 3.5% of the company’s shares are short sold.

Analyst Ratings Changes

CALC has been the subject of a number of research analyst reports. Weiss Ratings raised CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 27th. Guggenheim started coverage on CalciMedica in a research note on Thursday, August 20th. They issued a “buy” rating on the stock. UBS Group reiterated a “neutral” rating on shares of CalciMedica in a research report on Thursday, August 13th. HC Wainwright reissued a “neutral” rating on shares of CalciMedica in a research note on Wednesday, July 29th. Finally, Wall Street Zen cut shares of CalciMedica from a “sell” rating to a “strong sell” rating in a report on Saturday, September 12th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $50.00.

CalciMedica Stock Down 1.6%

CalciMedica stock opened at $1.22 on Friday. The company has a quick ratio of 5.58, a current ratio of 4.96 and a debt-to-equity ratio of 1.63. The firm has a market cap of $8.42 million, a P/E ratio of -0.27 and a beta of 0.84. The business has a fifty day moving average of $1.56 and a two-hundred day moving average of $3.12. CalciMedica has a twelve month low of $1.00 and a twelve month high of $36.00.

CalciMedica (NASDAQ:CALC) last announced its quarterly earnings results on Tuesday, November 10th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.27) by $1.03. On average, analysts forecast that CalciMedica will post -1.93 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CalciMedica

An institutional investor recently raised its stake in CalciMedica stock. Renaissance Technologies LLC increased its holdings in shares of CalciMedica Inc. (NASDAQ:CALC) by 45.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 128,075 shares of the company’s stock after buying an additional 39,775 shares during the quarter. Renaissance Technologies LLC owned 0.81% of CalciMedica worth $69,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

CalciMedica Company Profile

CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious inflammatory and immune-mediated diseases. The company’s research centers on calcium release-activated calcium (CRAC) channels, which help regulate immune-cell activation and inflammatory responses. CalciMedica’s lead product candidate is zelnecirnon, formerly known as Auxora or CM4620. It is an investigational, selective CRAC channel inhibitor being evaluated as a potential treatment for acute inflammatory conditions, including severe acute pancreatitis and associated organ injury.